Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Hold" Rating by Jones Trading

Key Points

• Analysts at Jones Trading have reaffirmed a "hold" rating for Y-mAbs Therapeutics (NASDAQ:YMAB), while other firms have issued varying ratings, including an "outperform" with a lowered target price of $18.00 by Wedbush.
• The stock has suffered from recent downgrades, with Bank of America placing a "sell" rating and targeting a price of $3.00.
• Y-mAbs Therapeutics recently reported a quarterly earnings unexpected positive surprise with an EPS of ($0.12), surpassing the consensus estimate, alongside a revenue of $20.90 million.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) was downgraded by research analysts at Jones Trading from a "strong-buy" rating to a "hold" rating in a note issued to investors on Tuesday, August 5th, Marketbeat Ratings reports.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright decreased their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Oppenheimer cut their target price on shares of Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, May 29th. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price for the company. in a research note on Tuesday, April 22nd. Wedbush reiterated an "outperform" rating and issued a $18.00 target price (down previously from $21.00) on shares of Y-mAbs Therapeutics in a research note on Wednesday, May 28th. Finally, Truist Financial cut their target price on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Y-mAbs Therapeutics has a consensus rating of "Hold" and a consensus price target of $11.16.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB traded down $0.01 during trading on Tuesday, reaching $8.51. 1,129,891 shares of the company traded hands, compared to its average volume of 481,947. The stock's 50 day moving average price is $5.02 and its two-hundred day moving average price is $4.95. The company has a market cap of $385.33 million, a price-to-earnings ratio of -17.02 and a beta of 0.57. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.20. The company had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. Y-mAbs Therapeutics had a negative return on equity of 24.34% and a negative net margin of 26.03%. Equities research analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Brooklyn Investment Group raised its position in shares of Y-mAbs Therapeutics by 4,563.8% during the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock valued at $26,000 after acquiring an additional 5,796 shares during the last quarter. CWM LLC raised its position in shares of Y-mAbs Therapeutics by 203.0% during the 2nd quarter. CWM LLC now owns 7,121 shares of the company's stock valued at $32,000 after acquiring an additional 4,771 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at $46,000. Los Angeles Capital Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the 2nd quarter valued at $46,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Y-mAbs Therapeutics during the 1st quarter valued at $49,000. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.